Abstract
Pneumococcal conjugate vaccines (PCVs) have significant efficacy in preventing acute otitis media caused by vaccine-type pneumococcal serotypes. This article questions whether experiences with pneumococcal otitis can be applied to pneumococcal pneumonia, and examines whether PCVs have a class effect, meaning do different PCVs offer equivalent protection against the same outcome of pneumococcal disease. While PCVs appear to have a class effect in general, variability in serotype-specific antibody concentrations makes extrapolation from one vaccine to another difficult. Antibody concentrations or measurements of antibody functionality may provide a means to anticipate a predicted outcome in pneumococcal pneumonia for certain emergent vaccine candidates.
| Original language | English |
|---|---|
| Pages (from-to) | B16-B18 |
| Journal | Vaccine |
| Volume | 26 |
| Issue number | SUPPL. 2 |
| DOIs | |
| State | Published - 16 Jun 2008 |
Keywords
- Antibody
- Otitis
- Vaccine
ASJC Scopus subject areas
- Molecular Medicine
- General Immunology and Microbiology
- General Veterinary
- Public Health, Environmental and Occupational Health
- Infectious Diseases
